SV debuts a new, $400M fund with a big focus on biotech startups
After tweaking its name, SV Health Investors unveiled its sixth main fund with $400 million, a step down from its last big raise way …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
